GSK Coughs Up $40 M for Option on Nabi's Late-Stage Smoking Vaccine NicVAX
This article was originally published in The Pink Sheet Daily
Executive Summary
Glaxo must decide by end of Phase 3 whether to exercise its option for $58 million more, but either way it gets rights to develop a next-gen version.
You may also be interested in...
Glaxo Buys A Stake In Intercell And Gains Access To Patch Vaccine Techology
As part of the deal, the big drug maker gets the right to market experimental patch vaccines for traveler's diarrhea and pandemic flu.
Glaxo Buys A Stake In Intercell And Gains Access To Patch Vaccine Techology
As part of the deal, the big drug maker gets the right to market experimental patch vaccines for traveler's diarrhea and pandemic flu.
Infectious Opportunity? Nabi Biopharma Sells Staph A Vaccine To Glaxo For $46M
The sale will enable the little company to focus solely on its nicotine-addiction vaccine candidate, NicVAX.